ALK fusion

Analysis of CROWN data (1L lorlatinib vs crizotinib) in #ALK NSCLC by EML4-ALK fusion variant and TP53 status @JTOonline. Given the clear biologic differences between variants (v3 vs others), I think it's time to stratify by variant and tailor strategies. https://t.co/iqJzIc5KEe (@StephenVLiu)

Cemiplimab is an immunotherapy drug used to treat advanced non-small cell lung cancer (NSCLC). ROS1 fusion is a genetic variant in NSCLC, while EGFR mutation and ALK fusion are two other common NSCLC genetic variants. (@forista8)

Meta-analysis @JTOonline shows incidence of brain metastases in pts with NSCLC was 28.6%. Highest risk was in NSCLC with a fusion in #ALK (34.9%) or #RET (32.2%). Per-year incidence 0.17 in ALK, 0.16 in #EGFR, 0.13 in #ROS1, 0.12 in RET, 0.10 in #KRAS. https://t.co/3xZAUBMnCp (@StephenVLiu)

But don't forget about men too. My wife's best friend's never smoker husband presented with persistent dry cough😒 Dx w/ 7cm RML mass with supraclav node+😭 Squamous NSCLC, chemo refractory 😬 but... then found be ALK-fusion driven😁. Now in near-CR on Alectinib. 🙏🙏🙏🥂🏆😅✌️❤️ (@PatrickCMa1)

@JuliaRotow discussing the important therapeutics and research advances in ALK and ROS1 NSCLC at Miami Cancer Meeting. @ros1cancer @ALKPositiveinc @alk_fusion @IASLC @isliquidbiopsy TESTING TESTING TESTING! @LUNGevity @LuisERaez1 @edgardo_ny (@ChristianRolfo)

Resistance mechanisms in ALK fusion-positive lung cancer https://t.co/mjdAblRY0I (@MLPOncoData)

Great to see this collaborative study between @UPMCHillmanCC @JHUPath @MayoClinicPath @CLEClinicLabs. Tweetorial coming out soon, but if you are interested in Actionable Fusion Genes (FGFR2, ALK, BRAF, NRG1, RET and others) in #PancreaticCancer look to ITPNs of the #Pancreas. (@PancPathologist)

@DrClaudiomartin 🇦🇷guiding us on TKI activity in brain metastasis in EGFR and ALK drivers. A very important topic in NSCLC. #LALCA23 @IASLC 🇺🇾🎯🫁💊 @ogarrieta @HwakeleeMD @LuisERaez1 @EGFRResisters @ALKLungCancer @alk_fusion @isliquidbiopsy (@ChristianRolfo)

Hey #lcsm precision onc guru friends- you want to be an Alkemist and help w challenging case? Young pt w egfr ex19 del, nice response to osi for yr+, now progression incl CNS CNS specimen now shows STRN-ALK fusion along w ex19del. Getting SRS to resid CNS dx What is best syst tx? (@DrSteveMartin)

Fascinating case. #LCSM #tssmn Benign #Lung Adenoma Mimicking an Adenocarcinoma with EML4-ALK Gene Fusion https://t.co/3EZjs6NB6I @JonathanHyde_3 (@DavidCookeMD)

To the amazing community of #lungcancer advocates - please submit an abstract to showcase your work @AACR 2023 Meeting. @alk_fusion @ALK_Research @ALKLungCancer @EgfrUk @EGFRResisters @KRASKickers @metcrusaders @RETpositive @ros1cancer @LUNGevity @GO2forLungCancr @lcfamerica (@christine_lovly)

Awesome #TumorBoardTuesday by @LeciaSequist discussing #ALK fusion+ #NSCLC Chooing #TKI: 🧠 mets > Lorlatinib vs Brigatinib, NO 🧠 mets > Alectinib vs Btigatinib, type of #mutation_matters #LCAM #LCSM @ALKLungCancer @TumorBoardTues (@FawziAbuRous)

Great start to #LCAM, @LeciaSequist tackles #ALK+ #lungcancer @TumorBoardTues @ALKpositiveINT @alk_fusion #LCSM 📆11/1 8pm EST👇🏽 (@Latinamd)

Great start to #LCAM, @LeciaSequist tackles #ALK+ #lungcancer @TumorBoardTues @ALKpositiveINT @alk_fusion #LCSM 📆11/1 8pm EST👇🏽 (@Latinamd)

Great start to #LCAM, @LeciaSequist takles #ALK+ #lungcancer @TumorBoardTues @ALKpositiveINT @alk_fusion 📆11/1 8pm EST (@Latinamd)

50s, EML4-ALK fusion, pdl1 30%, brain Mets on present. Started alectinib, favorable response. Cns only progression 1 y later tx SBRT, 3 m later wider brain progression and systemic progression. After WBRT? @JackWestMD @mjfidler @PatelOncology @LeciaSequist @ChristineBestv1 (@SyedMAhmedMDPhD)

⭐️#FantasticFriday ! What a delight to join the amazing @DrSarcoma & terrific @alexdrilon to discuss all the latest & greatest developments in fusion driven cancers #NTRK #RET #ROS1 #ALK & beyond #tissueagnostic #PrecisionMedicine @OncoAlert (@VivekSubbiah)

ALKi treatment provides remarkable responses and clinical benefit in previously treated patients with #ALK fusion-positive #GI malignancies. @OG_priorities @OG_priorities @oncologician @IsabellaD_onco https://t.co/wHYe3qoXHg (@Dr_Ivanoncologo)

@DrHendifar @PancPathologist have had success w/ #ALK fusion in metastatic #PDAC following #FOLFIRINOX responsive to #alectinib then acquired alectinib-resistant ALK mutations G1202R and V1180L on G360, then w/benefit to 3rd-gen ALK inh #lorlatinib https://t.co/JnI2dntOfv #pancsm ()

Shout out to my fellow #GIonc crew. Have a young Burmese patient with EMLA-ALK fusion mutation via NGS in metastatic #crcsm, progressing on 2nd line FOLFOXIRI. Very scant data in alectinib in this setting. Anyone with clinical experience? @pashtoonkasi @marklewismd @doctorC369 (@realbowtiedoc)

The only parallel experience I have is a complete block of approval for alectinib despite appeals for an ALK fusion positive cholangiocarcinoma patient of mine. I'm trying to get it from the company 🙏 (@MPishvaian)

Now out by @margheambro1 ALK inh in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series. Thanks to all coauthors ! @Marzia_DelRe @KlempnerSam @JamesClearyMD @paomanca @alexdrilon Is ALK an agnostic target? https://t.co/IbHjFOYkg1 (@FilippoPietran4)

Ntrk-fusion spindle cell tumor Or other fusion involving alk, braf… (@BattistellaMD)

This is the second publication I’ve shared with @FordePatrick this month, the first shared our experience treating ALK or ROS1 fusion tumors (excluding lung cancer) with crizotinib as part of the NCI MATCH https://t.co/1Kz3RwJeR0 (@AMansfieldMD)

Great slides from Dr. @oncoOuLungCA on the relative IC50 values for the available #ALK kinase inhibitors in EML4-ALK variant 1 versus variant 3 and preclinical sensitivity data. #TTLC22 @IASLC @ALKLungCancer @alk_fusion #LCSM (@StephenVLiu)

Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA https://t.co/ozJcFGTCvC Should we be✅for genomic drivers in atypical lung carcinoid? Our case📖suggests maybe we should. @denisegococo @NANETS1 @CarcinoidNETs @netcanceraware @HealingNET1 @CureNETs (@drjasonstarr)

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC https://t.co/Wvv0xjHr0B #ALK #lungcancer #PrecisionMedicine @MNagasaka @ViolaWZhu and Dr. Shannon S. Zhang. (@oncoOuLungCA)

Atypical Lung #Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA https://t.co/KrQovp1yB7 @drjasonstarr @NANETS1 @MayoClinic #NeuroendocrineTumors #LetsTalkAboutNETs (@CarcinoidNETs)

@NarjustDumaMD & @StephenVLiu discuss ALK-fusion positive #NSCLC w/@JessicaJLinMD from MA General Hospital Cancer Center & @harvardmed and @bensolomon1 professor/consultant medical oncologist @ the Peter MacCallum Cancer Center in Australia. Listen: https://t.co/MHzakj0m86 #LCSM (@IASLC)

Report in @ESMO_Open on liquid biopsy results post TKI therapy for 116 pts with #ALK fusion+ NSCLC. G1202R resistance mutation more common in EML4-ALK fusion variant 3, L1196M more in v1. More compound and complex mutations seen with use of multiple TKIs. https://t.co/ID201mkX4C (@StephenVLiu)

Another one in #lungcancer for @OncoKB : CLIP1-LTK fusions sensitizing to ALK/ROS inhibitor lorlatinib w/ a reported robust patient response 0.4% in Japanese pt cohort Good thing I follow @RielyMD! Beautiful @Nature study by Koichi Goto & SS Kobayashi https://t.co/zSMKSiBCqg (@CDebyaniPhD)

🎯From withdrawal of life support to going to pre-school Another story of #precisionmedicine in action 👉Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma @NEJM @OncoAlert 🧬🧪 https://t.co/CWeY73WeqN (@VivekSubbiah)

Alexander E. Drilon, MD @alexdrilon of Memorial Sloan-Kettering @sloan_kettering discusses “Targeting Gene Fusions in Adenocarcinoma (ALK, ROS1, RET, NTRK)” at today’s 39th Annual PER CFS Symposium in NYC! #lcsm @GoToPER (@FrommeyerSteven)

Dr. @alexdrilon reviews fusions in NSCLC like #ALK #ROS1 #NTRK #RET and #NRG1. Leads off with critical point: RNA-based NGS will increase sensitivity to many of these fusions (and METex14). Important to know the details of the test you order/receive! #LCSM @gotoPER #LCAM (@StephenVLiu)

Here’s the most recent numbers from Dr. @graokane & colleagues in #PancreaticCancer. NTRK fusion rates are less than 1% overall, but if a patient is confirmed KRAS wild type, make sure to look for fusions using a RNA based assay. Similar data with ALK. https://t.co/VWyACNpMSm (@Aiims1742)

In our small validation with the Idylla Cartridge NTRK3 fusions are not well detected, specially in Thyroid Papillary Cancer were high levels of basal NTRK expresión can give a false negative result. Intreagued by this false +, ok in Met exon 14, ret fusión, Ros1 and Alk fusion (@GRecondoMD)

From 👉🏼A child near death with an ALK-fusion–positive high-grade glioma refractory to standard treatment had a dramatic response when treatment with lorlatinib was begun 👉🏼To 👉🏼At this time, the child is attending preschool and has normal neurologic function. (@VivekSubbiah)

🚨🎯 The Lazarus phenomenon 👉Precision Oncology in action. Eyes just teared up reading this case of Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma @NEJM @OncoAlert https://t.co/7ZTrsQsPco (@VivekSubbiah)

A toddler with an aggressive brain tumor was running out of treatment options. Now he’s in kindergarten. Read in @NEJM how the ALK-fusion gene & precision medicine lorlatinib changed the disease’s course. https://t.co/nXHQFJGYwE @DrGilesRobinson @DrAditiBagchi #childhoodcancer (@StJudeResearch)

Another reminder in #JCOPO @ASCO_pubs that when pathogenic gene fusions are found, they're often viable targets (as this #ALK fusion in breast cancer). Mutations are much more variable so important to note the details when you get your reports. https://t.co/EzCttpWMsP (@StephenVLiu)

Honored to participate in the @cancerGRACE Targeted Therapies Patient Forum to discuss treatment of ALK-fusion positive NSCLC. Please consider joining us this Saturday for lively discussion! #LCSM @ALKLungCancer @JackWestMD (@chulkimMD)

SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy https://t.co/JyXMiVd1dS (@AndresFCardonaZ)